Cherry Ma


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Cherry Ma focuses her practice on corporate finance and capital markets. Cherry advises clients on Hong Kong initial public offerings, mergers and acquisitions, regulatory compliance, and general corporate matters.


  • English
  • Cantonese
  • Mandarin


  • Hong Kong


  • The Chinese University of Hong Kong, P.C.L.L.
  • The Chinese University of Hong Kong, J.D.; B.A.
  • Sipai Health Technology Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
  • 3D Medicines Inc. in its US$52 million IPO and listing on the Hong Kong Stock Exchange
  • China VAST Industrial Urban Development (6166.HK) and its controlling shareholder, Profit East Limited, in the US$285 million all-cash take private proposal by China Jinmao Holdings Group Limited (817.HK)